• Guideline Summary
  • NGC:011018
  • 2016 Jul 20

Non-Hodgkin's lymphoma: diagnosis and management.

  • Guideline Summary
  • NGC:010715
  • 2005 Feb 17 (revised 2015 Mar 31)

Rituximab in lymphoma and chronic lymphocytic leukemia: a clinical practice guideline, version 3.

  • Guideline Summary
  • NGC:010735
  • 2015 Jun

Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia.

  • Guideline Summary
  • NGC:010624
  • 2005 Aug (revised 2014 Dec)

Colorectal cancer. The diagnosis and management of colorectal cancer.

  • Guideline Summary
  • NGC:010737
  • 2012 Nov (revised 2015 Feb)

Systemic therapy for well and moderately differentiated unresectable pancreatic neuroendocrine tumours.

  • Guideline Summary
  • NGC:010926
  • 2016 Feb 2

Systemic treatment of acute myeloid leukemia (AML).

  • Guideline Summary
  • NGC:010011
  • 2013 Aug

Everolimus in combination with exemestane for treating advanced HER2-negative hormone-receptor-positive breast cancer after endocrine therapy.

  • Guideline Summary
  • NGC:010617
  • 2008 May (revised 2014 Nov)

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA 142).

  • Guideline Summary
  • NGC:010730
  • 2013 Apr (revised 2015 Apr)

Castration-resistant prostate cancer: AUA guideline.

  • Guideline Summary
  • NGC:010683
  • 2014

ACR Appropriateness Criteria® resectable stomach cancer.

  • Guideline Summary
  • NGC:010373
  • 2013 Sep

Optimal use of taxanes in metastatic breast cancer (MBC).

  • Guideline Summary
  • NGC:009295
  • 2004 Aug (revised 2012 Aug)

Practice parameters for the management of colon cancer.

  • Guideline Summary
  • NGC:010253
  • 2010 Jul (revised 2013 Apr)

Epithelial ovarian, fallopian tube, and primary peritoneal cancer.

  • Guideline Summary
  • NGC:010675
  • 1998 (revised 2014)

ACR Appropriateness Criteria® recurrent rectal cancer.

  • Guideline Summary
  • NGC:010464
  • 2007 (revised 2014)

ACR Appropriateness Criteria® rectal cancer--metastatic disease at presentation.

  • Guideline Summary
  • NGC:009311
  • 2012 Aug

Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer.